How We WorkOrder NowSupport Privacy

Mid-Cap Stocks Alert: Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) and Teva Pharmaceutical Industries (NASDAQ:TEVA)

on 09/05/2013

New York, NY – (Net PR News) – 05/09/2013–smartOTCis the premiere destination for Investors and novices alike who wish to receive information on fast moving OTC stocks and undiscovered companies. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.

Sign up For Our No. 1 Rated Stock Newsletter to make Huge Profitshttp://www.smartotc.com

Alexza Pharmaceuticals Inc. (NASDAQ:ALXA) shares were up on Wednesday, following the firm reported that Teva Pharmaceutical Industries Ltd., one of the world’s biggest drug firms, would promote is agitation drug, Adasuve, in the US.

The firms reported on Wednesday that Teva will be accountable for all US commercial and clinical-related activities, consisting of an obligatory post-approval study.

How stock of Alexza Pharmaceuticals Inc gained investors attention on Wednesday? Find out in this report

Teva will also have the right to study the drug as a cure for other neurological disorders. Alexza, of Mountain View, Calif., will develop the drug and supply it to Teva.

The Israeli firm will pay Alexza (ALXA) $40 million upfront and it could make a further $195 million in milestone payments formed on the conclusion of post-approval studies and sales targets.

Alexza will also get royalties on sales of the drug, and Teva will lend Alexza almost $25 million to support Adasuve’s activities over the coming five years.

How stock of Teva Pharmaceutical Industries gained investors attention on Wednesday? Find out in this report

Teva Pharmaceutical Industries (NASDAQ:TEVA) and Alexza Pharmaceuticals hit an exclusive US license and supply deal for Adasuve inhalation powder for the cure of agitation linked with schizophrenia or bipolar I disorder in adults.

Israel-located Teva will be accountable for all US commercial and clinical activities for Adasuve and has gained rights to conduct further clinical trials for possible new indications in neurological disorders.

Alexza will be in charge for manufacturing and supplying Adasuve to Teva for commercial sales and clinical trials.

About Us:

smartOTC is the premiere destination for Investors and novice alike who wish to receive information on fast moving OTC penny stocks and undiscovered companies. We are a marketing firm that releases paid reports on undiscovered companies looking to tell their stories. Most of these companies are considered penny stocks and trade on the Pink Sheet or OTC BB market. Our daily alerts help investors cut their research time in half as we send out small cap and penny stock alerts that are displaying signs of a potential rally.

While penny stocks pose a much more significant risk factor compared to large cap stocks, their lure of quick gains makes it a trading choice for many small time and beginner investors. There is nothing wrong with investments into penny stocks, the best advice is to do your own research and consult with your own financial professional. smartOTC reports and alerts should only be used as a starting point for your own due diligence.

Disclaimer:

PLEASE NOTE WELL: This report/release/advertisement is a commercial advertisement and is for general information purposes only. We are engaged in the business of marketing and advertising companies for monetary compensation.

Smartotc.com and its employees are not a Registered Investment Advisor, Broker Dealer or a member of any association for other research providers in any jurisdiction whatsoever and we are not qualified to give financial advice. The disclaimer is to be read and fully understood before using our site, or joining our email list. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. All content in our releases is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities.

Read Our Full Disclaimer at http://www.smartotc.com/disclaimer

Source: smartotc Posted Thu, May 09, 2013 13:29 - Permalink